Early hypercholesterolemia contributes to vasomotor dysfunction and injury associated atherogenesis that can be

Kathleen G Raman1, Robin E Gandley, Jennifer Rohland

  • 1Division of Vascular Surgery, Department of Surgery, University of Pittsburgh, Pittsburgh, Pa 15213, USA.

Journal of Vascular Surgery
|December 18, 2010
PubMed

Insights

Early hypercholesterolemia impairs blood vessel function and contributes to vascular injury. Nitric oxide (NO) therapy, specifically via iNOS gene transfer, effectively inhibits atheroma formation, suggesting potential therapeutic roles.

Area of Science:

  • Cardiovascular Biology
  • Vascular Medicine
  • Atherosclerosis Research

Background:

  • Atherosclerosis impairs nitric oxide (NO)-dependent vasodilation, contributing to vasomotor dysfunction.
  • The role of early hypercholesterolemia, prior to significant vascular changes, in vasomotor dysfunction and vascular injury remains unclear.

Purpose of the Study:

  • To investigate if early hypercholesterolemia induces vasomotor dysfunction and vascular injury.
  • To assess the efficacy of NO therapy in protecting against vascular injury in hypercholesterolemic settings.

Main Methods:

  • Oxidized low-density lipoprotein (oxLDL) and inducible NO synthase (iNOS) gene transfer effects on smooth muscle cell proliferation were measured.
  • Vasomotor function of carotid arteries from hypercholesterolemic (ApoE KO) and wild-type mice on different diets was assessed using an arteriograph system, before and after injury.
  • The impact of iNOS gene transfer on vascular remodeling and function post-injury was examined.

Main Results:

  • OxLDL increased smooth muscle cell proliferation; iNOS expression inhibited this effect, even with oxLDL present.
  • Hypercholesterolemia reduced endothelium-dependent vasodilation in uninjured arteries, with effects worsening with duration.
  • Vascular injury severely disrupted vasodilation, but recovery was observed by 4 weeks; ApoE KO mice developed atheromatous lesions post-injury, unlike controls.

Conclusions:

  • Early hypercholesterolemia impairs endothelial function, dependent on duration and severity.
  • Vascular injury in hypercholesterolemia promotes atherogenesis, involving distinct mechanisms from endothelial dysfunction.
  • iNOS gene transfer effectively inhibited atheroma formation, supporting early hypercholesterolemia management and NO-based therapies.
Abstract

Related Concept Videos

Nitric Oxide Signaling Pathway01:28

Nitric Oxide Signaling Pathway

Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure to...
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...